FrancophonIA/ELRC3.0 huggingface dataset:
English: Distearoylphosphatidylcholine Dipalmitoylphosphatidylglycerol Sodium Palmitic acid
Croatian: Prašak: makrogol 4000 distearilfosfatidilkolin natrijev fosfatidilglicerildipalmitat palmitatna kiselina
English: METHOD OF ADMINISTRATION
Croatian: NAČIN PRIMJENE LIJEKA
English: How SonoVue is given
Croatian: Kako davati SonoVue
English: Type I clear glass pre-filled syringe containing 5 mL sodium chloride 9 mg/mL (0.9%) solution for injection.
Croatian: I koja sadrži 5 ml 0,9%-tne (9 mg/ml) otopine natrijevog klorida za injekciju.
English: Excipients
Croatian: Nepoznato
English: INFORMATION IN BRAILLE
Croatian: Prijava nuspojava
English: Rare (may affect up to 1 in 1,000 people)
Croatian: Rijetke (mogu se javiti u do 1 na 1 000 osoba)
English: If you are taking any of the following:
Croatian: Ako uzimate:
English: If you had these symptoms prior to treatment with lenalidomide, tell your doctor about any change in these symptoms.
Croatian: Ako ste imali te simptome prije početka liječenja lenalidomidom, obavijestite svojeg liječnika o svim promjenama simptoma.
English: Adopted at the 14-17 May 2018 PRAC
Croatian: Usvojeno na sjednici PRAC-a 14. - 17. svibnja 2018.
English: Patients should also be advised to inform their partner or caregivers about their treatment, since they may notice symptoms that the patient is not aware of.
Croatian: Bolesnicima također treba savjetovati da obavijeste svoje partnere ili njegovatelje o liječenju jer oni mogu primijetiti simptome kojih bolesnik nije svjestan.
English: Possible side effects (under corresponding frequencies):
Croatian: Moguće nuspojave (uz odgovarajuću učestalost):
English: What you need to know before you use REVLIMID [...]
Croatian: Što morate znati prije nego što počnete uzimati REVLIMID [...]
English: The following medicines may increase the effects of Eliquis and increase the chance for unwanted bleeding:
Croatian: Sljedeći lijekovi mogu pojačati učinke lijeka Eliquis i povećati rizik od neželjena krvarenja:
English: At any time during or after your treatment, tell your doctor or nurse immediately if you: experience blurred, loss of or double vision, difficulty speaking, weakness in an arm or a leg, a change in the way you walk or problems with your balance, persistent numbness, decreased sensation or loss of sensation, memory loss or confusion.
Croatian: U bilo kojem trenutku za vrijeme ili nakon liječenja, odmah obavijestite svojeg liječnika ili medicinsku sestru ako: vam se pojavi zamagljen vid, gubitak vida ili dvostruka slika, poteškoće u govoru, slabost u ruci ili nozi, promjene u načinu hodanja ili problemi s ravnotežom, utrnulost koja ne prolazi, smanjen osjet ili gubitak osjeta, gubitak pamćenja ili smetenost.
English: Pembrolizumab - Aseptic meningitis (EPITT no 19115)
Croatian: Pembrolizumab - Aseptični meningitis (EPITT br. 19115)
English: PML was reported several months to several years after starting the treatment with lenalidomide.
Croatian: Slučajevi PML-a zabilježeni su nekoliko mjeseci do nekoliko godina nakon početka liječenja lenalidomidom.
English: What you need to know before you take Lixiana/Roteas Other medicines and Lixiana/Roteas
Croatian: Što morate znati prije nego počnete uzimati Lixiana/Roteas Drugi lijekovi i Lixiana/Roteas
English: If PML is confirmed, lenalidomide must be permanently discontinued.
Croatian: Ako je PML potvrđen, primjena lenalidomida mora se trajno prekinuti.
English: Physicians should monitor patients at regular intervals and should consider PML in the differential diagnosis in patients with new or worsening neurological symptoms, cognitive or behavioural signs or symptoms.
Croatian: Liječnici trebaju pratiti bolesnike u redovitim intervalima i trebaju uzeti u obzir PML u diferencijalnoj dijagnozi u bolesnika s novim ili pogoršavajućim neurološkim simptomima, kognitivnim ili bihevioralnim znakovima ili simptomima.
English: If PML is suspected, further dosing must be suspended until PML has been excluded.
Croatian: Ako se sumnja na PML, daljnje doziranje mora se obustaviti do isključenja PML-a.
English: Summary of product characteristics 4.4.
Croatian: Sažetak opisa svojstava lijeka 4.4.
English: Undesirable effects Nervous system disorders Frequency ‘rare': meningitis (aseptic)
Croatian: Poremećaji živčanog sustava Učestalost „rijetko”: meningitis (aseptični)
English: Lenograstim; lipegfilgrastim; pegfilgrastim - Pulmonary haemorrhage (EPITT no 19181)
Croatian: Lenograstim; lipegfilgrastim; pegfilgrastim - Plućna hemoragija (EPITT br. 19181)
English: Special warnings and precautions for use Interaction with other medicinal products affecting haemostasis
Croatian: Posebna upozorenja i mjere opreza pri uporabi Interakcija s drugim lijekovima koji utječu na hemostazu
English: The evaluation for PML should be based on neurological examination, magnetic resonance imaging of the brain, and cerebrospinal fluid analysis for JC virus (JCV) DNA by polymerase chain reaction (PCR) or a brain biopsy with testing for JCV.
Croatian: Dijagnostička obrada za utvrđivanje PML-a treba se temeljiti na neurološkom pregledu, magnetskoj rezonanciji mozga, analizi cerebrospinalnog likvora na DNK virusa JC (JCV) metodom lančane reakcije polimerazom (PCR) ili biopsijom mozga s testiranjem na JCV.
English: Lenalidomide - Progressive multifocal leukoencephalopathy (PML) (EPITT no 19130)
Croatian: Lenalidomid - progresivna multifokalna leukoencefalopatija (PML) (EPITT br. 19130)
English: Inflammation of the membrane around the spinal cord and brain, which may present as neck stiffness, headache, fever, eye sensitivity to light, nausea and vomiting (meningitis)
Croatian: Upala ovojnice oko leđne moždine i mozga, koja se može očitovati kao ukočenost vrata, glavobolja, vrućica, osjetljivost oka na svjetlost, mučnina i povraćanje (meningitis)
English: Cases have generally been reported in patients taking concomitant dexamethasone or prior treatment with other immunosuppressive chemotherapy.
Croatian: Ti su slučajevi obično prijavljeni u bolesnika koji istodobno uzimaju deksametazon ili koji su prethodno liječeni drugom imunosupresivnom kemoterapijom.
English: *Note: Stated frequencies are applicable for pegfilgrastim; for lipegfilgrastim and lenograstim the frequency is to be calculated by the MAHs.
Croatian: *Napomena: Navedene učestalosti primjenjive su za pegfilgrastim; za lipegfilgrastim i lenograstim učestalost trebaju utvrditi nositelji odobrenja za stavljanje lijeka u promet.
English: Despite these findings, there may be individuals with a more pronounced pharmacodynamic response when antiplatelet agents are coadministered with apixaban.
Croatian: Usprkos tim nalazima, neki pojedinci mogu imati izraženiji farmakodinamički odgovor kod istodobne primjene antitrombocitnih lijekova i apiksabana.
English: SSRIs/SNRIs: As with other anticoagulants the possibility may exist that patients are at increased risk of bleeding in case of concomitant use with SSRIs or SNRIs due to their reported effect on platelets (see section 4.4).
Croatian: SSRI-jevi/SNRI-jevi: Kao i s drugim antikoagulansima, može postojati mogućnost povećanog rizika od krvarenja u bolesnika u slučaju istodobne primjene sa SSRI-jevima i SNRI-jevima zbog njihovog zabilježenog učinka na trombocite (vidjeti dio 4.4.).
English: Cases of progressive multifocal leukoencephalopathy (PML), including fatal cases, have been reported with lenalidomide.
Croatian: Pri primjeni lenalidomida prijavljeni su slučajevi progresivne multifokalne leukoencefalopatije (PML), uključujući slučajeve sa smrtnim ishodom.
English: What you need to know before you take Eliquis Other medicines and Eliquis
Croatian: Što morate znati prije nego počnete uzimati Eliquis
English: Eliquis should be used with caution when coadministered with SSRIs/SNRIs or NSAIDs (including acetylsalicylic acid) because these medicinal products typically increase the bleeding risk.
Croatian: Potreban je oprez kod istodobne primjene lijeka Eliquis s SSRI-jevima/SNRI-jevima ili NSAIL-ovima (uključujući acetilsalicilatnu kiselinu), jer oni obično povećavaju rizik od krvarenja.
English: Apixaban; edoxaban - Drug interaction between apixaban or edoxaban and selective serotonin reuptake inhibitors (SSRI) and/or serotonin and noradrenaline reuptake inhibitors (SNRI) leading to increased risk of bleeding (EPITT no 19139)
Croatian: Apiksaban; edoksaban - interakcija između apiksabana ili edoksabana i selektivnih inhibitora ponovne pohrane serotonina (SSRI-jevi) i/ili inhibitora ponovne pohrane serotonina i noradrenalina (SNRI-jevi), što dovodi do povećanog rizika od krvarenja (EPITT br. 19139)
English: Coughing up blood (haemoptysis) - uncommon* Bleeding from the lung (pulmonary haemorrhage) - rare*
Croatian: Iskašljavanje krvi (hemoptiza) - manje često* Krvarenje iz pluća (plućna hemoragija) - rijetko*
English: These include acetylsalicylic acid (ASA), P2Y12 platelet inhibitors, other antithrombotic agents, fibrinolytic therapy, selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs), and chronic nonsteroidal anti-inflammatory drugs (NSAIDs) (see section 4.5).
Croatian: Među njima su acetilsalicilatna kiselina (ASK), inhibitori trombocitnog receptora P2Y12, drugi antitrombotički lijekovi, fibrinolitička terapija, selektivni inhibitori ponovne pohrane serotonina (SSRI) i/ili inhibitori ponovne pohrane serotonina i noradrenalina (SNRI) i kronična primjena nesteroidnih protuupalnih lijekova (NSAIL) (vidjeti dio 4.5).
English: • anti-inflammatory and pain-relieving medicines (e.g. naproxen or acetylsalicylic acid (aspirin))
Croatian: • protuupalne lijekove i lijekove protiv boli (npr. naproksen ili acetilsalicilatnu kiselinu)
English: Care is to be taken if patients are treated concomitantly with selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs), or non-steroidal anti-inflammatory drugs (NSAIDs), including acetylsalicylic acid.
Croatian: Nužan je oprez ako se bolesnici istodobno liječe selektivnim inhibitorima ponovne pohrane serotonina (SSRI) ili inhibitorima ponovne pohrane serotonina i noradrenalina (SNRI) ili nesteroidnim protuupalnim lijekovima (NSAIL), uključujući acetilsalicilatnu kiselinu.
English: • antidepressant medicines called selective serotonin re-uptake inhibitors or serotonin
Croatian: • lijekove za liječenje depresije koji se nazivaju selektivni inhibitori ponovne pohrane serotonina ili inhibitori ponovne pohrane serotonina i noradrenalina
English: Interaction with other medicinal products and other forms of interaction Anticoagulants, antiplatelets, and NSAIDs and SSRIs/SNRIs
Croatian: 4.5. Interakcije s drugim lijekovima i drugi oblici interakcija Antikoagulansi, antitrombocitni lijekovi, i NSAIL-ovi i SSRI-jevi/SNRI-jevi
English: - medicines for high blood pressure or heart problems (e.g., diltiazem) - antidepressant medicines called selective serotonin re-uptake inhibitors or serotonin
Croatian: - lijekovi za liječenje visokog krvnog tlaka ili srčanih tegoba (npr. diltiazem) - lijekovi za liječenje depresije koji se nazivaju selektivni inhibitori ponovne pohrane serotonina ili inhibitori ponovne pohrane serotonina i noradrenalina
English: A significant increase in bleeding risk was reported with the triple combination of apixaban, ASA and clopidogrel in a clinical study in patients with acute coronary syndrome (see section 4.4).
Croatian: U kliničkom ispitivanju u bolesnika s akutnim koronarnim sindromom prijavljeno je značajno povećanje rizika od krvarenja kod primjene trojne kombinacije apiksabana, ASK-a i klopidogrela (vidjeti dio 4.4).
English: Apixaban
Croatian: Apiksaban
English: Edoxaban
Croatian: Edoksaban
English: Additional follow-up and evaluation may be warranted if no alternative diagnosis can be established.
Croatian: Ako se ne postavi druga dijagnoza, potrebno je daljnje praćenje i procjenjivanje bolesnika.
English: Undesirable effects Respiratory, thoracic and mediastinal disorders Haemoptysis (uncommon*) Pulmonary haemorrhage (rare*)
Croatian: Poremećaji dišnog sustava, prsišta i sredoprsja Hemoptiza (manje često*)
English: Interaction with other medicinal products and other forms of interaction Anticoagulants, platelet aggregation inhibitors, SSRIs/SNRIs and NSAIDs
Croatian: Antikoagulansi, inhibitori agregacije trombocita, SSRI-jevi/SNRI-jevi i NSAIL-ovi
English: Concomitant use of medicines affecting haemostasis may increase the risk of bleeding.
Croatian: Antikoagulansi, antitrombotici i trombolitici Interakcija s drugim lijekovima koji utječu na hemostazu Istodobna primjena lijekova koji utječu na hemostazu može povećati rizik od krvarenja.
English: The recommended dose is 100 mg in patients aged 12 years and above, and 40 mg in patients aged 6 to 11 years.
Croatian: Preporučena doza je 100 mg u bolesnika u dobi od 12 ili više godina i 40 mg u bolesnika u dobi od 6 do 11 godina.
English: In children, eosinophilic asthma is rare and the data available are therefore limited.
Croatian: U djece je eozinofilna astma rijetka, stoga su dostupni podatci ograničeni.
English: In addition, a reduction in corticosteroid dose was considered clinically relevant, given the potential complications of long-term corticosteroid treatment.
Croatian: Osim toga, smanjenje doze kortikosteroida smatralo se klinički značajnim s obzirom na moguće komplikacije dugotrajnog liječenja kortikosteroidima.
English: What measures are being taken to ensure the safe and effective use of Nucala?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Nucala?
English: The most common side effect with Nucala (which may affect more than 1 in 10 people) is headache.
Croatian: Najčešća nuspojava lijeka Nucala (koja se može javiti u više od 1 na 10 osoba) jest glavobolja.
English: The medicine is given by injection under the skin of the upper arm, thigh or abdomen (belly) once every 4 weeks.
Croatian: Lijek se daje injekcijom pod kožu nadlaktice, bedra ili abdomena (trbuha) jedanput u četiri tjedna.
English: This helps to reduce inflammation, resulting in a reduction in asthma attacks and improvement of symptoms.
Croatian: To pomaže u smanjenju upale, što smanjuje broj napadaja astme i ublažava simptome.
English: Nucala received a marketing authorisation valid throughout the EU on 2 December 2015.
Croatian: Lijek Nucala dobio je odobrenje za stavljanje u promet koje je na snazi u EU-u od 2. prosinca 2015.
English: Over half (37 of 69) of the patients given Nucala were able to reduce their daily corticosteroid dose by more than 50% to a dose of 5 mg or less, and 10 of them were able to stop corticosteroids altogether, compared with about a third of those given placebo (22 of 66, of whom 5 were able to stop corticosteroids).
Croatian: Više od polovice (37 od 69) bolesnika koji su uzimali lijek Nucala bilo je u mogućnosti smanjiti dnevnu dozu kortikosteroida za više od 50 %, na dozu od 5 mg ili manju dozu, a 10 ih je bilo u stanju potpuno obustaviti liječenje kortikosteroidima u usporedbi s otprilike trećinom onih koji su primali placebo (22 od 66, od kojih je njih 5 moglo potpuno obustaviti liječenje kortikosteroidima).
English: Side effects reported with Nucala are carefully evaluated and any necessary action taken to protect patients.
Croatian: Nuspojave prijavljene za lijek Nucala pažljivo se procjenjuju i poduzimaju se potrebne mjere za zaštitu bolesnika.
English: By attaching to interleukin-5, mepolizumab blocks its action and thereby reduces the numbers of eosinophils.
Croatian: Vežući se za interleukin-5, mepolizumab blokira njegovo djelovanje i time smanjuje broj eozinofila.
English: The Agency concluded that the data available indicate that Nucala acts in a similar way in adults and children and the results in adults therefore also apply to children with eosinophilic asthma.
Croatian: Agencija je zaključila da dostupni podatci pokazuju da lijek Nucala djeluje na sličan način u odraslih i u djece, a rezultati u odraslih stoga se također odnose i na djecu s eozinofilnom astmom.
English: In adults the reduction seen in severe asthma attacks and consequent need for hospital treatment was considered important and outweighed the low risk of side effects.
Croatian: U odraslih se smanjenje teških napada astme i posljedične potrebe za bolničkim tretmanom smatra značajnim i nadmašuje mali rizik od nuspojava.
English: What is Nucala and what is it used for?
Croatian: Što je Nucala i za što se koristi?
English: Other information about Nucala
Croatian: Ostale informacije o lijeku Nucala
English: An additional study was carried out in children aged 6 years to 11 years which showed that a dose of 40 mg Nucala given under the skin produced comparable levels of active substance in the body to those seen with standard doses in adults.
Croatian: Dodatno ispitivanje provedeno u djece u dobi od 6 do 11 godina pokazalo je da je doza od 40 mg lijeka Nucala dana pod kožu proizvela razine aktivne tvari u tijelu koje su usporedive s onima utvrđenima kod standardnih doza u odraslih osoba.
English: The second study involved 576 adults and adolescents given Nucala every 4 weeks for 28 weeks.
Croatian: Drugo je ispitivanje uključivalo 576 odraslih osoba i adolescenata koji su lijek Nucala uzimali svaka 4 tjedna tijekom 28 tjedana.
English: What are the risks associated with Nucala?
Croatian: Koji su rizici povezani s lijekom Nucala?
English: Why is Nucala authorised in the EU?
Croatian: Zašto je lijek Nucala odobren u EU-u?
English: The main measure of effectiveness in these studies was the number of severe attacks (exacerbations) of asthma that occurred during treatment, which was reduced by about half in patients given Nucala.
Croatian: Glavno mjerilo djelotvornosti ovih ispitivanja bilo je broj teških napada (egzacerbacija) astme tijekom liječenja, što je smanjeno za otprilike polovicu u bolesnika koji su primili lijek Nucala.
English: The European Medicines Agency decided that Nucala's benefits are greater than its risks and it can be authorised for use in the EU.
Croatian: Europska agencija za lijekove zaključila je da koristi od lijeka Nucala nadmašuju s njim povezane rizike te da lijek može biti odobren za primjenu u EU-u.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Nucala have been included in the summary of product characteristics and the package leaflet.
Croatian: Preporuke i mjere opreza kojih se zdravstveni radnici i bolesnici trebaju pridržavati u cilju sigurne i učinkovite primjene lijeka Nucala nalaze se u sažetku opisa svojstava lijeka i u uputi o lijeku.
English: Reactions at the site of injection and back pain are common, affecting up to 1 patient in 10.
Croatian: Uobičajene su i reakcije na mjestu uboda i bol u leđima, koje se mogu javiti u najviše 1 na 10 bolesnika.
English: The reduction in eosinophil levels in the blood achieved in children was also comparable with that seen with standard doses in adults.
Croatian: Smanjenje razine eozinofila u krvi postignuto u djece također je bilo usporedivo sa smanjenjem utvrđenim kod standardnih doza u odraslih osoba
English: It is used with other medicines in patients whose asthma is severe and not well controlled with previous treatments.
Croatian: Koristi se s drugim lijekovima u bolesnika s teškim oblikom astme koja se prethodnim terapijama nije mogla dobro kontrolirati.
English: The third study involved 135 mostly adult patients with eosinophilic asthma severe enough to need regular treatment by mouth with corticosteroids (potent anti-inflammatory medicines such as prednisone and prednisolone), and the main measure of effectiveness was how much the corticosteroid dose could be reduced using Nucala for 24 weeks compared with placebo.
Croatian: Treće je ispitivanje uključivalo 135 većinom odraslih bolesnika s eozinofilnom astmom dovoljno ozbiljnom da bi bilo potrebno redovito liječenje oralnim kortikosteroidima (snažni protuupalni lijekovi kao što su prednizon i prednizolon), a glavno mjerilo djelotvornosti bilo je koliko se doza kortikosteroida mogla smanjiti lijekom Nucala tijekom 24 tjedna u usporedbi s placebom.
English: An overview of Nucala and why it is authorised in the EU
Croatian: Pregled informacija o lijeku Nucala i zašto je odobren u EU-u
English: For more information about using Nucala, see the package leaflet or contact your doctor or pharmacist.
Croatian: Za više informacija o primjeni lijeka Nucala pročitajte uputu o lijeku odnosno obratite se liječniku ili ljekarniku.
English: The active substance in Nucala, mepolizumab, is a type of protein called a monoclonal antibody, which attaches to a specific substance in the body.
Croatian: Djelatna tvar u lijeku Nucala, mepolizumab, vrsta je proteina koji se naziva monoklonsko protutijelo, koji se veže za određene tvari u tijelu.
English: In eosinophilic asthma, symptoms are associated with having too many eosinophils (a type of white blood cell) in the blood and in phlegm in the lungs.
Croatian: Simptomi eozinofilne astme povezani su s prevelikim brojem eozinofila (vrste bijelih krvnih stanica) u krvi te u sluzi u plućima.
English: How does Nucala work?
Croatian: Kako djeluje Nucala?
English: As for all medicines, data on the use of Nucala are continuously monitored.
Croatian: Kao i za sve lijekove, podatci o primjeni lijeka Nucala kontinuirano se prate.
English: The benefits of Nucala in severe eosinophilic asthma that is not well controlled by previous treatment have been shown in three main studies, in which it was compared with a placebo (dummy) injection.
Croatian: Prednosti lijeka Nucala kod teške eozinofilne astme koja prethodnim liječenjem nije bila dobro kontrolirana dokazane su u trima glavnim ispitivanjima u kojima je lijek uspoređen s injekcijom placeba (prividno liječenje).
English: Mepolizumab attaches to a substance called interleukin-5 which encourages the production and survival of eosinophils.
Croatian: Mepolizumab se veže na tvar interleukin-5, koja potiče stvaranje i preživljavanje eozinofila.
English: Nucala can only be obtained with a prescription and should be prescribed by a doctor experienced in identifying and treating severe eosinophilic asthma.
Croatian: Nucala se izdaje samo na recept, a treba ga propisati liječnik s iskustvom u prepoznavanju i liječenju teške eozinofilne astme.
English: Nucala is intended for long-term treatment.
Croatian: Lijek Nucala namijenjen je za dugotrajnu primjenu.
English: Nucala is an asthma medicine used to treat patients aged 6 years and above with a particular type of asthma called eosinophilic asthma.
Croatian: Nucala je lijek protiv astme koji se koristi za liječenje bolesnika u dobi od 6 godina i starijih s određenom vrstom astme zvanom eozinofilna astma.
English: Nucala is available as a solution in a prefilled pen or syringe or as a powder that comes in a vial and is made up into an injection.
Croatian: Dostupan je kao otopina u napunjenoj brizgalici ili štrcaljki ili u bočici kao prašak za otopinu za injekciju.
English: What benefits of Nucala have been shown in studies?
Croatian: Koje su koristi od lijeka Nucala utvrđene u ispitivanjima?
English: The patient and carer can use Nucala prefilled pen or syringe themselves once they have been trained, whereas the vial is only for use by a healthcare professional.
Croatian: Bolesnik ili njegovatelj mogu nakon odgovarajuće obuke samostalno primjenjivati lijek u napunjenim brizgalicama ili štrcaljkama, dok lijek u bočicama mogu primjenjivati samo zdravstveni radnici.
English: The first study involved 616 adults and adolescents given Nucala every 4 weeks for a year, in addition to their regular asthma medicines.
Croatian: Prvo je ispitivanje uključivalo 616 odraslih osoba i adolescenata koji su uz redovito uzimanje lijekova protiv astme uzimali lijek Nucala svaka 4 tjedna tijekom godine dana.
English: For the full list of side effects and restrictions with Nucala, see the package leaflet.
Croatian: Potpuni popis nuspojava i ograničenja povezanih s primjenom lijeka Nucala potražite u uputi o lijeku.
English: Nucala contains the active substance mepolizumab.
Croatian: Lijek Nucala sadrži djelatnu tvar mepolizumab.
English: How is Nucala used?
Croatian: Kako se Nucala primjenjuje?